Contact LinkedIn Twitter

Betina og Henrik

An introduction to Zealand

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn and Boehringer Ingelheim.

The company’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-US) as Lyxumia® and has it under regulatory review in the US. The license agreement with Sanofi covers also LixiLan, which is the reference name for the fixed-ratio, single-product combination of lixisenatide and insulin glargine 100 Units/mL (Lantus®). LixiLan is under regulatory priority review by the US FDA and Sanofi has planned for regulatory submission in the EU in Q1 2016.

Zealand’s proprietary pipeline includes: ZP4207 (single-dose) for rescue treatment of severe hypoglycemia (Phase II); ZP1848 for Short Bowel Syndrome (Phase II); ZP4207 (multiple-dose) for better hypoglycemia management in diabetes (Phase I); ZP2929 for diabetes/obesity (Phase I); and several preclinical peptide therapeutics.

The company is based in Copenhagen (Glostrup), Denmark.

Zealand has ~110 employees of which 80% work in research and development.

Follow us on Twitter:Twitter @ZealandPharma

Follow us on LinkedIn